Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 9:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 897 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Once Weekly Clear all

Conditions: Autistic Disorder, Insomnia
Interventions: supplemental liquid melatonin, flavored liquid or liquid supplemental melatonin; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 4 Years to 10 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Breast Cancer
Interventions: GDC-0941, Placebo, Paclitaxel; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 47
States / cities: Sedona, Arizona • Anaheim, California • Encinitas, California + 43 more

Conditions: Secondary Hyperparathyroidism, Chronic Kidney Disease
Interventions: Etelcalcetide, Cinacalcet, Oral Placebo, Intravenous Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 683 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 41
States / cities: Azusa, California • Bakersfield, California • Chula Vista, California + 37 more

Conditions: Systemic Lupus Erythematosus
Interventions: A-623, Placebo Comparator; Drug · Other
Lead sponsor: Anthera Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 547 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 14
States / cities: Birmingham, Alabama • Long Beach, California • Los Angeles, California + 11 more

Conditions: Childhood Cancer
Interventions: Attention Training, Placebo; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 8 Years to 16 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Obesity, Overweight, Obstructive Sleep Apnoea
Interventions: NNC0487-0111, Placebo (matched to NNC0487-0111); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 20
States / cities: Gilbert, Arizona • Bradenton, Florida • Naples, Florida + 16 more

Conditions: Type 2 Diabetes
Interventions: Bydureon, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 29
States / cities: Anaheim, California • Chino, California • Los Angeles, California + 26 more

Conditions: Chronic Inflammatory Demyelinating Polyneuropathy
Interventions: Imeroprubart, Placebo; Drug
Lead sponsor: Immunovant Sciences GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 33
States / cities: Tucson, Arizona • Carlsbad, California • Mission Hills, California + 28 more

Conditions: Breast Cancer
Interventions: Pembrolizumab (K), Placebo (P), Paclitaxel (X), Doxorubicin (A), Epirubicin (E), Cyclophosphamide (C), Endocrine therapy, Radiation therapy, Surgery; Biological · Drug · Radiation + 1 more
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2031
U.S. locations: 45
States / cities: Daphne, Alabama • Goodyear, Arizona • Tucson, Arizona + 39 more

Conditions: Hypercholesterolemia, Coronary Heart Disease
Interventions: Mipomersen sodium, Placebo; Drug
Lead sponsor: Kastle Therapeutics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 62
States / cities: Birmingham, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 51 more

Conditions: Diabetes Mellitus, Type 2
Interventions: NNC0662-0419, Semaglutide, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 23
States / cities: Lancaster, California • Lomita, California • Long Beach, California + 20 more

Conditions: Rheumatoid Arthritis
Interventions: Placebo, JNJ-38518168 (3 mg), JNJ-38518168 (10 mg), JNJ-38518168 (30 mg), Methotrexate; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 9
States / cities: Huntsville, Alabama • Gilbert, Arizona • Covina, California + 6 more

Conditions: Psychedelic Microdosing Effects on Mood, Cognition, Subjective Well-being and MRI
Interventions: Psliocybin, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Chronic Kidney Disease, Anemia
Interventions: Rilonacept; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 27
States / cities: Alexander City, Alabama • Muscle Shoals, Alabama • Cerritos, California + 24 more

Conditions: Neoplasm Cervix
Interventions: Curcumin C3 Complex, Placebo; Drug
Lead sponsor: Lisa Flowers; Other
Eligibility: 21 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Cocaine Dependence
Interventions: levodopa/carbidopa 400/100 BID; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 131 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Exercise-related Amenorrhea
Interventions: Transdermal 17Beta-estradiol, progesterone, Ethinyl Estradiol + Desogestrel, Sham Comparator; Drug · Dietary Supplement
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 14 Years to 21 Years · Female only
Enrollment: 121 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Fibromyalgia
Interventions: Intervention Group, Placebo Comparator: Control Group; Behavioral
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Recurrent Genital Herpes Simplex Type 2
Interventions: ABI-1179, ABI-1179 Placebo; Drug
Lead sponsor: Assembly Biosciences; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 103 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 4
States / cities: Kansas City, Missouri • Rochester, New York • Seattle, Washington

Conditions: HIV Infections
Interventions: LDMTX, Placebo, Folic acid; Drug · Dietary Supplement
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 40 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 22
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 18 more

Conditions: Obese Adults
Interventions: VK2735 Drug, Placebo; Drug
Lead sponsor: Viking Therapeutics, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Lake Forest, California • Miami, Florida

Conditions: Multiple Sclerosis
Interventions: Laquinimod, Placebo, Avonex®; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 31 more

Conditions: Pancreatic Cancer
Interventions: Gemcitabine, Nab-paclitaxel, Paricalcitol, Placebo; Drug · Other
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 2
States / cities: Boston, Massachusetts • Philadelphia, Pennsylvania

Conditions: Depressive Disorder, Treatment-Resistant
Interventions: Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 719 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 53
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 50 more

Search by objective public record fields.

Melatonin for Sleep in Children With Autism

A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Participants With Locally Recurrent or Metastatic Breast Cancer

Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet

PEARL-SC Trial: A Study of the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus Erythematosus

Inattention in Childhood Cancer Survivors

AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

Study to Evaluate the Effect of BYDUREON on 24-hour Glucose Control in Metformin Treated Patients With Type 2 Diabetes.

Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

Safety and Efficacy of Mipomersen (ISIS 301012) As Add-on Therapy in High Risk Hypercholesterolemic Patients

A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

A Dose Range Finding Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis in Spite of Treatment With Methotrexate

Psilocybin Microdosing on Cognition, Mood and Quality of Life

Study of the Safety and Effectiveness of Rilonacept (IL-1 Trap) Administered Subcutaneously in Subjects With Non Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) and Anemia

Topical Curcumin for HPV Related Cervical Disease

Striatal Effective Connectivity to Predict Treatment Response in Cocaine Misuse

Fat Mediated Modulation of Reproductive and Endocrine Function in Young Athletes

Qigong Exercise May Benefit Patients With Fibromyalgia

A Study to Assess the Safety, Pharmacokinetics, and Tolerability of ABI-1179 in Healthy Subjects and in Subjects Seropositive for HSV-2 With Recurrent Genital Herpes

Safety and Effectiveness of Low-Dose Methotrexate for Reducing Inflammation in HIV-Infected Adults on ARV Medications

A Phase 1 Study of VK2735 in Obese Adults Without Comorbidities

BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)

Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer

A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression